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Background and purpose: Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and
provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard
(IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 substudy within CHHiP trial. We present a
pre-planned analysis of the impact of IGRT on dosimetry and acute/late pelvic side effects using gastroin-
testinal and genitourinary clinician and patient-reported outcomes (PRO) and evaluate efficacy.
Materials and methods: CHHiP is a randomised phase 3, non-inferiority trial for men with localised pros-
tate cancer. 3216 patients were randomly assigned to conventional (74 Gy in 2 Gy/fraction (f) daily) or
moderate hypofractionation (60 or 57 Gy in 3 Gy/f daily) between October 2002 and June 2011. The
IGRT substudy included a second randomisation assigning to no-IGRT, IGRT-S (standard CTV-PTV mar-
gins), or IGRT-R (reduced CTV-PTV margins). Primary substudy endpoint was late RTOG bowel and uri-
nary toxicity at 2 years post-radiotherapy.
Results: Between June 2010 to July 2011, 293 men were recruited from 16 centres. Median follow-up is
56.9(IQR 54.3–60.9) months. Rectal and bladder dose-volume and surface percentages were significantly
lower in IGRT-R compared to IGRT-S group; (p < 0.0001). Cumulative proportion with RTOG grade  2
toxicity reported to 2 years for bowel was 8.3(95% CI 3.2–20.7)%, 8.3(4.7–14.6)% and 5.8(2.6–12.4)%
and for urinary 8.4(3.2–20.8)%, 4.6(2.1–9.9)% and 3.9(1.5–9.9)% in no IGRT, IGRT-S and IGRT-R groups
respectively. In an exploratory analysis, treatment efficacy appeared similar in all three groups.
Conclusion: Introduction of IGRT was feasible in a national randomised trial and IGRT-R produced dosi-
metric benefits. Overall side effect profiles were acceptable in all groups but lowest with IGRT and
reduced margins.
ISRCTN: 97182923.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 142 (2020) 62–71 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Intensity-modulated radiotherapy (IMRT) enables dose escala-
tion to the prostate target volume, with low gastrointestinal or
genitourinary toxicity [1–4]. The success of radical prostate radio-
therapy depends on accurate delivery of high dose conformal
radiotherapy to a defined target volume. Image guided radiother-
apy (IGRT) with daily online imaging has the potential to improve
prostate localisation, consequently improving treatment accuracyand reducing the required clinical (CTV) to planning (PTV) target
volume margin [5]. This may reduce the amount of normal tissue
receiving target doses, and consequently toxicity [6]. Intrafraction
motion and outlining uncertainties still necessitate a small margin
around the CTV [5].
In addition to optimising prostate radiotherapy techniques,
there has been interest in the exploitation of fraction sensitivity
of prostate cancer through hypofractionation [7–9]. This has been
successfully examined within the UK multicentre randomised con-
trolled trial (Conventional or Hypofractionated High-dose Intensity
Modulated Radiotherapy in Prostate Cancer; CHHiP) which aimed
J. Murray et al. / Radiotherapy and Oncology 142 (2020) 62–71 63to compare the efficacy and toxicity of conventional and hypofrac-
tionated radiotherapy using high-quality radiation techniques.
Within the trial, 3216 patients were enrolled from 71 centres
within the UK between October 2002 and June 2011 [10].
During the latter stages of the CHHiP trial, IGRT became avail-
able in participating treatment centres. To assess this technology
the CHHiP IGRT phase 2 substudy was developed. We aimed to
determine the feasibility and generalisability of IGRT in the context
of a multicentre trial and assess acute and late toxicity. A patient
reported outcome (PRO) protocol was subsequently integrated into
the substudy. To our knowledge, this is the only randomised study
undertaken evaluating daily prostate image-guided IMRT with and
without reduced PTV margins.Table 1
Baseline characteristics by treatment group (n = 293).
No IGRT
N = 48
n (%)
IGRT – S
N = 137
n (%)
IGRT – R
N = 108
n (%)
Randomisation option
No IGRT v IGRT-S v IGRT-R 16 (33) 13 (9) 13 (12)
No IGRT v IGRT-S 32 (67) 32 (23) –
IGRT-S v IGRT-R – 92 (67) 95 (88)
Age (years)
Median (IQR) 71 (66–73) 72 (66–75) 71 (67–75)
Range 57–80 53–82 54–80
Time from histological confirmation of prostate cancer to randomisation
(wks)
Median (IQR) 16 (13–25) 17 (13–27) 18 (13–25)
Range 6–350 3–278 4–265
T stage (clinical assessment)
T1 16 (33) 46 (34) 43 (40)
T2 27 (56) 83 (61) 56 (52)
T3 5 (10) 8 (6) 9 (8)
Grading group(Gleason score)Materials and methods
Study design and participants
CHHiP is a randomised phase 3, non-inferiority trial which
recruited men with localised prostate cancer (pT1b-T3aN0M0)
[10]. Patients were randomly assigned (1:1:1) to conventional 74
Gray (Gy) in 2 Gy/fraction (f) daily or one of two hypofractionated
schedules giving 60 Gy or 57 Gy in 3 Gy/f daily. Patients were all
treated with IMRT [11].
The IGRT substudy was approved by Central London REC1
Research Ethics Committee (10/H0718/31) and implemented in
June 2010. Men who had entered the CHHiP trial were eligible
for the IGRT substudy with additional consent and provided they
had no contraindication to implanted fiducial markers or a hip
prosthesis or fixation which would interfere with positional imag-
ing. Following dose/fractionation randomisation in the main CHHiP
trial, minimisation was used to assign IGRT substudy patients in a
1:1:1 ratio to either no-IGRT – using standard CHHiP planning
margins, IGRT using standard CHHiP planning margins (IGRT-S),
or IGRT with reduced planning margins (IGRT-R). Radiotherapy
centre and dose/fractionation schedule were used as balancing fac-
tors. Neither patients nor clinicians were blinded to allocation. Six-
teen UK radiotherapy centres took part in the IGRT substudy.
Centres could choose, depending on previous IGRT experience, to
randomise to all three treatment technique options or to the 2-
way randomisations: no IGRT versus IGRT-S or IGRT-S versus
IGRT-R. Four centres used the 3-way randomisation, five centres
randomised to no-IGRT vs IGRT-S and seven centres randomised
to IGRT-S vs IGRT-R. In 2014, a patient reported outcomes (PRO)
assessment was introduced to collect data at a single time point
at least three years post randomisation. This separate protocol
received ethical approval from the NRES Committee South West
– Central Bristol (14/SW/1071).1 (3 + 3) 13 (27) 42 (31) 31 (29)
2 (3 + 4) 30 (63) 61 (45) 55 (51)
3 (4 + 3) 4 (8) 32 (23) 19 (18)
4 (4 + 4, 3 + 5, 5 + 3) 1 (2) 2 (1) 3 (3)
PSA (pre-hormone treatment) (ng/ml)
Median (IQR) 9.5 (6.8–15.2) 9.7 (6.9–12.5) 8.3 (6.9–11.4)
Mean (SD) 11.1 (4.9) 10.3 (4.6) 9.1 (3.8)
PSA (ng/ml)
0.0–4.99 2 (4) 13 (10) 12 (11)
5.0–9.99 23 (48) 57 (42) 60 (56)
10.0–19.99 20 (42) 65 (48) 36 (33)
20.0–49.99 3 (6) 2 (2) 0
NCCN Risk group
Low 2 (4) 16 (12) 17 (16)
Medium 38 (79) 109 (80) 80 (74)
High 8 (17) 12 (9) 11 (10)
CHHiP treatment allocation
74 Gy/37Fr 18 (38) 44 (32) 33 (31)
60 Gy/20Fr 15 (31) 48 (35) 37 (34)
57 Gy/19Fr 15 (31) 45 (33) 38 (35)Treatment
Patients randomised to treatment with IGRT, either had fiducial
markers inserted into the prostate using trans-rectal ultrasound
guidance or soft tissue matching if using the TomoTherapy sys-
tem. Fiducial markers were implanted with antibiotic cover
approximately 2 weeks prior to the radiotherapy planning scan.
Patient positioning was supine and target and treatment planning
volumes have been previously described [11]. Radiotherapy was
planned and delivered using an integrated simultaneous boost
technique (SIB) with three different target volumes and dose levels
as previously detailed [12] and illustrated in Table S1. In the no-
IGRT and IGRT-S arms the standard CHHiP CTV to PTV posterior
margins of 10 mm/5 mm/0 mm were used. In the IGRT-R arm,
these posterior margins were 6 mm/3 mm/0 mm. Mandatory dose
constraints were defined for both target coverage and avoidance of
normal tissues including rectum, bowel, bladder and femoral heads(Table S2). Treatment was delivered with 6–15 MV photons with
multileaf collimators to shape beams.
Patients randomised to no-IGRT had offline portal imaging to
verify treatment accuracy; the match to bony landmarks was to
be within 3 mm. Patients receiving IGRT had daily pre-treatment
imaging and any observed set-up error 2 mmwas corrected prior
to treatment. No post-correction imaging was taken. A prospective
quality-assurance programme was designed as an integral part of
the study [13] including specific aspects for the IGRT substudy
(Supplementary material).Trial assessments
Pre-trial staging investigations included PSA, lymph node
assessment by MRI or CT, and bone scan. Histology was assessed
from diagnostic TRUS guided biopsies (or TURP specimens) and
reported using the Gleason system.
Toxicity experienced from fiducial marker insertion was
recorded using CTCAE grading [14].
Pre-hormone and pre-radiotherapy clinical assessments used
Late Effects of Normal Tissues Subjective-Objective Management
(LENT-SOM) [15] and the Royal Marsden Hospital (RMH) grading
[16]. Clinical assessment of acute toxicity was made weekly during
radiotherapy and at weeks 10, 12 and 18 from the start of radio-
therapy using the Radiation Therapy Oncology Group (RTOG) scor-
ing system [17]. Late toxicity was assessed at 6, 12, 18 and
Fig. 1. CONSORT diagram.
64 IGRT for prostate cancer24 months then annually to 5 years using RTOG, LENTSOM and
RMH scoring systems.
In the PRO substudy, data was collected at a single time point
using the Expanded Prostate Cancer Index Composite (EPIC) ques-
tionnaire, (EPIC-50 used for bowel and urinary domains and EPIC-
26 for sexual and hormonal domains) [18], the Vaizey Incontinence
[19], Short Form 12 (SF-12) [20] and International Index of Erectile
Function (IIEF-5) [21] questionnaires. Questionnaires were sent
directly from participating centres to patients (following confirma-tion of health status) who were at least three years from complet-
ing treatment. A single reminder letter was sent.
For each patient, treatment planning data (planning CT, dose dis-
tribution and organ contours) were uploaded using dedicated anal-
ysis software (VODCA.MSSMedical Software Solutions, Hagendorn,
Switzerland). Using in-house code, all radiotherapy plans were
converted into equivalent dose in 2 Gy per fraction, using Withers
formula [22] with an a/b ratio of 3 Gy for rectum and 5 Gy for
Fig. 2. Boxplots illustrating dose volume and dose surface histograms, the calculated volume and surface percentages for rectum (A) and bladder (B) normal tissues by IGRT
group and dose KEY: All doses are equivalent dose in 2 Gy fractions. Red boxplots represent patients treated with no IGRT, green boxplots are those patients treated with IGRT
standard margins and blue boxplots are those patients treated with IGRT reduced margins.
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surface (DSH) histograms were generated for rectum and bladder.Statistical considerations
The IGRT substudy was non-comparative and powered to assess
toxicity independently within each treatment technique group
using Simon single stage design with exact p-values [23]. The pri-
mary endpoint was proportion of patients with RTOG bladder or
bowel toxicity of grade 2 at two years from starting radiotherapy.
Secondary endpoints included acute toxicity, prevalence of late
radiation induced toxicity, time to late radiation induced toxicity,
toxicity associated with fiducials and feasibility of delivery of IGRT
in a multi-centre setting. Efficacy has been included as exploratory
analyses. Ninety-one patients were required (with 79 or more
remaining toxicity-free) in each group to give 80% power to detect
a 10% RTOG bladder/bowel grade 2 toxicity rate at 2 years with
IGRT assuming a 20% toxicity rate with no IGRT (alpha 3.4%). Sam-
ple size was not calculated for the PRO substudy, all eligible IGRT
substudy patients were invited to participate.Analysis methods
All analyses have been presented according to randomly allo-
cated treatment technique group. Analyses of side effects includedall data available at each time point for patients who received at
least one fraction of radiotherapy (unless otherwise stated). Worst
acute bladder and bowel toxicity was calculated using worst grade
reported during the first 18 weeks from start of radiotherapy. For
the primary endpoint, only patients with a 2-year RTOG toxicity
assessment were included in the denominator, although a sensitiv-
ity analysis was conducted using all randomised patients. The pro-
portion of patients with RTOG bladder or bowel toxicity of grade
2 at 2 years were presented together with exact binomial 95%
confidence intervals. Time to first occurrence of late radiation
induced side effects were analysed using Kaplan Meier method
to calculate the cumulative proportion with events reported on
2-year assessment form for each scoring system. Time was mea-
sured from start of radiotherapy. Patients not experiencing an
event were censored at date of last toxicity assessment or at date
of death for deceased patients. The log-rank test was used to com-
pare no IGRT versus IGRT-S and IGRT-S versus IGRT-R with a signif-
icance level of 1%, to account for multiple comparisons.
Biochemical/clinical failure was defined as time to first PSA failure
(PSA value greater than nadir +2 ng/ml with a consecutive confir-
matory PSA value) or prostate cancer recurrence (local, lymph
node, pelvic or distant). Patients event free at the time of analysis
were censored at their last know PSA assessment.
Statistical analyses were based on a data snapshot taken on
18th May 2016 (except for efficacy analyses which were based
Fig. 2 (continued)
66 IGRT for prostate canceron a snapshot taken on 3rd April 2018 to maximise data maturity).
All analyses were performed using STATA Version 13.1. Patient
reported outcomes were scored in accordance with the recom-
mended scoring manuals [24,25] and presented as descriptive
statistics by treatment group. The Vaizey questionnaire is scored
on a continuous scale, with minimum score, 0 representing perfect
continence and a maximum score, 24 representing total inconti-
nence [19]. Patients were divided into 3 categories for Vaizey total
score according to tertiles and dose data presented. In health
related quality of life, the clinically meaningful change is defined
as a mean change score exceeding half the standard deviation of
baseline value [26]. As there was no baseline data available for this
patient group, the mean and standard deviation values from the
main CHHiP trial QoL substudy [27] (Table S3) were used to define
a threshold score for a meaningful change for the EPIC bowel and
urinary domain scores.
Results
Two-hundred and ninety-three patients (48 no-IGRT, 137 IGRT-
S and 108 IGRT-R) from 16 radiotherapy centres across the UK
were randomised between July 2010 and June 2011. Baseline char-
acteristics were balanced between treatment technique groups
(Table 1) with median age of 71 (IQR 66–74), median pre-
hormone PSA of 9.5 ng/ml (IQR 6.8–12.40) and 12%, 77% and 11%
low, intermediate and high risk respectively. At the time of thedata snapshot for toxicity, median follow-up was 56.9 months
(IQR 54.3–60.9) and for efficacy 73.3 (IQR 64.9–74.6) months.
Three patients received no radiotherapy (one withdrew con-
sent, one died and one biochemically progressed prior to radiother-
apy). Adherence to randomly allocated treatment technique was
high (Fig. 1): three no-IGRT patients received IGRT, nine IGRT-S
patients did not receive standard CHHiP planning margins and four
IGRT-R patients did not have reduced margins. Two-hundred and
twenty-five patients had image guidance using fiducials, 11
patients were treated using TomoTherapy and six patients using
CT on rails.
Median (IQR) rectum volumes were 65 (59–77), 68 (56–86) and
67 (58–85) cm3 for the no-IGRT, IGRT-S and IGRT-R groups respec-
tively. Corresponding figures for bladder volumes were 277 (200–
379), 249 (167–375) and 281 (180–386) cm3 (Table S4). A sum-
mary of DVH and DSH for rectum and bladder by treatment group
are shown in Fig. 2. Both rectal and bladder dose volume and sur-
face percentages were consistently statistically lower in the IGRT-R
compared to IGRT-S group (Table S5). Adherence to rectal dose
constraints of 68% to 100% of prescribed dose and the bowel con-
straint was seen for 98% of patients, with all patients within the
IGRT-R group achieving all these constraints (Table S6-S7).
Toxicity associated with fiducial marker insertion was minimal
with 19/190 (10%) reporting grade 1 and one patient reporting
grade 2 haemorrhage. Six (3%) patients had an infection, three
grade 1, two grade 2 and one grade 3. Worst RTOG bowel toxicity
Fig. 3. Acute RTOG bowel (A) and bladder (B) toxicity by timepoint and IGRT group. Distribution of grade and prevalence.
J. Murray et al. / Radiotherapy and Oncology 142 (2020) 62–71 67reported during 18 weeks from starting radiotherapy was grade 2
in 13/48 (27%), 38/135 (28%) and 26/107 (24%) of no-IGRT, IGRT-S
and IGRT-R patients respectively. Corresponding figures for RTOG
bladder grade 2 were 21/48 (44%), 71/135 (53%) and 48/107
(45%). By week 18, majority of toxicity had resolved with grade
2 bowel toxicity reported in 0% no-IGRT, 5% IGRT-S and 2%
IGRT-R patients and RTOG bladder grade 2 reported in 3% no-
IGRT, 8% IGRT-S and 4% IGRT-R patients (Fig. 3).
At two years, RTOG bowel and bladder toxicity was low across
all treatment technique groups (Table S8) with 13 out of 274 (4.7%)
patients assessed reporting any RTOG grade 2 toxicity, which was
the primary endpoint of the substudy. The upper limits of 95% con-
fidence intervals ruled out greater than 20% toxicity within each
treatment technique group. Moderate to severe RTOG bowel toxi-
city was similar across treatment groups, with 1/46 (2%), 3/125
(2%) and 2/103 (2%) no-IGRT, IGRT-S and IGRT-R patients reporting
grade 2 at 2 years. Cumulative proportion with grade 2 RTOG
bowel toxicity reported to 2 years was 8.3% (95%CI 3.2–20.7),
8.3% (4.7–14.6%) and 5.8% (2.6–12.4%) for no-IGRT, IGRT-S and
IGRT-R groups respectively (Fig. 4A and Table S9). RMH and LENT-
SOM scales showed similar low levels of moderate to severe bowel/
rectum toxicity. RMH bowel grade 2 showed reduced toxicity in
the IGRT-R group compared to IGRT-S with borderline statistical
significance (HR = 0.39, 95%CI 0.18–0.83, p = 0.012).
Moderate to severe RTOG bladder toxicity was similar across
treatment technique groups, with 1/46 (2%), 4/125 (3%) and
2/103 (2%) no-IGRT, IGRT-S and IGRT-R patients reporting grade2 at 2 years. Cumulative proportion of RTOG bladder grade 2
toxicity by 2 years was low for all groups with the least toxicity
reported in the IGRT-R group: 8.4 (3.2–20.8)%, 4.6 (2.1–9.9)% and
3.9 (1.5–9.9)% for no-IGRT, IGRT-S and IGRT-R groups respectively
(Fig. 4B and Table S9). The RMH and LENTSOM scales reported
higher incidences of bladder toxicity compared to RTOG but with
a similar trend across groups. There was no evidence of significant
differences between treatment technique groups.
A total of 193/265 (72.8%) PRO booklets were completed at a
median of 50.3 months (IQR 47.8–52.0) from randomisation. Base-
line characteristics were balanced between treatment technique
groups and there were no significant differences between patients
who did and did not complete the PRO booklet (Table S10). There
was no evidence of any differences between treatment technique
groups for EPIC or Vaizey summary scores (Table 2), with no sug-
gestion of a worsening of Vaizey score with increased dose volume
or dose surface at any dose level (Table S11). Median DVH and DSH
values were calculated for patients whose EPIC bowel and urinary
scores were below and above the threshold level previously
defined (Table S3). There was a trend that patients whose score
were below the cut-point had higher dose volume or surface levels
(Fig. S1).
Thirty-three patients had biochemical/clinical failure reported
(4, 20 and 9 in no IGRT, IGRT-S and IGRT-R groups respectively)
(Table S12 and Fig. S2). Five-year biochemical/clinical failure free
survival was 91.1 (95% CI 77.9–96.6), 85.2 (95%CI 77.7–90.3) and
93.1 (95%CI 86.1–96.7) for no IGRT, IGRT-S and IGRT-R groups
Fig. 4. Bowel (A) and bladder (B) toxicity assessed using RTOG, RMH and LENTSOM by timepoint and IGRT group. Distribution and cumulative proportion with grade 1 and
grade 2 radiation induced late toxicity. KEY: For cumulative proportion plots: red = No IGRT, Green = IGRT-S, Blue = IGRT-R. Solid lines indicated grade 1 events and dashed
lines indicate grade 2 events NB. Late toxicity data have been included in stacked bar charts if they were reported within 6 weeks of the 6 month visit, within 3 months of
the 12–24 month visits and within 6 months of the 36 and 48 month visits.
68 IGRT for prostate cancerrespectively. Fourteen patients had recommenced androgen depri-
vation therapy, nine had local recurrence, seven had lymph node/
pelvic recurrence and seven had distant recurrence. Twenty-
seven patients had died, three from prostate cancer, twenty-
three from other reasons and one unknown.Discussion
We have demonstrated that implementation of IGRT was feasi-
ble in a multi-centre trial in the UK. Recruitment of patients was
swift and completed within one year. Accrual peaked at 45patient/month, with 16 radiotherapy centres participating. Subse-
quently IGRT has become part of the national guidelines recom-
mended treatment pathway. This emphasises the importance of
clinical trials as a vehicle to introduce advanced radiotherapy tech-
nology. Limitations of this substudy include its relatively small
size, uneven randomisation between treatment technique groups
and PRO assessment at a single time point. Yet, to our knowledge,
this is the only randomised prospective study evaluating no-IGRT,
IGRT and treatment margins using the same planning techniques.
We found minimal toxicity associated with insertion of fiducial
markers. Dosimetric assessments showed that reduced margins in
the IGRT-R group resulted in rectal and bladder volumes receiving
Fig. 4 (continued)
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margins, this was also seen for surface dose. The mean dose to rec-
tal surface in the IGRT-S group was 33.9(±5.1) Gy and similar to
that previously reported of 34.4(±7.2) Gy using IG-IMRT [28]
despite differences in dose prescription and margining techniques.
As expected, mean dose to rectum in the IGRT-R group was signif-
icantly lower at 28.9(±4.2) Gy. Similarly, mean dose to bladder sur-
face was 26.6(±9.2) Gy/20.5(±6.6)Gy for IGRT-S/IGRT-R groups
respectively, both lower than previously reported (33.1 ± 10.9 Gy)
[28]. Late GI toxicity was consistently reported less often using
the three clinician based scores in the IGRT-R group. However,
the improved rectal dosimetry did not translate into a statisticallysignificant benefit in acute or late GI toxicity, with the possible
exception of grade 2 RMH GI side-effects. This perhaps unex-
pected result may relate to the low level of side-effects seen in
all randomised dose/fractionation groups in the main CHHiP trial
which used strict normal tissue dose constraints and a SIB tech-
nique limiting dose to the seminal vesicles [10]. The lack of reduc-
tion in acute and late GU side effects may relate to similar doses to
the urethra in all treatment technique groups. It may be the com-
bination of dose/volume/fractionation employed in the trial has
reached a plateau for radiotherapy side effects and other patient
[29], radiogenomic [30] or microbiota [31] related factors become
more important in determining residual symptoms. We believe it
Table 2
Bowel and urinary domain scores using EPIC questionnaire and scoring system by treatment group at a median follow-up of 50.3 months (IQR: 47.8–52.0 months).
No IGRT IGRT-S IGRT-R
No. of pts with data Median (IQR) No. of pts With data Median (IQR) No. of pts with data Median (IQR)
Bowel function 29 96.4 (89.3–100) 89 92.9 (85.7–96.4) 75 96.4 (85.7–100)
P-value 0.2101 0.5002
Bowel bother 29 96.4 (87.5–100) 83 92.9 (85.7–100) 74 92.9 (85.7–100)
P-value 0.4751 0.9092
Bowel summary 29 94.6 (89.3–98.2) 84 94.6 (87.5–96.4) 74 92.9 (87.5–98.2)
P-value 0.2181 0.5862
Urinary function 28 97.5 (92.2–100) 87 100 (89.2–100) 75 95 (88.4–100)
P-value 0.9411 0.4092
Urinary bother 28 82.1 (74.1–93.8) 80 85.7 (71.4–92.9) 70 85.7 (75.9–92.9)
P-value 0.9471 0.4562
Urinary incontinence 27 100 (82.4–100) 79 93.8 (85.5–100) 71 93.8 (79.3–100)
P-value 0.9851 0.4732
Irritative/Obstructive 28 88.4 (78.6–96.0) 79 89.3 (80.7–92.9) 70 89.3 (85.7–96.4)
P-value 0.8611 0.4542
Urinary summary 27 88.9 (80.6–96.9) 79 88.9 (78.7–95.8) 71 89.6 (84–94.8)
P-value 0.9451 0.7332
Vaizey total score 27 4 (1–5.5) 84 4 (1–7) 72 4 (1–6)
0.0481 0.8212
1 Comparison of No IGRT and IGRT-S groups.
2 Comparison of IGRT-S and IGRT-R groups.
70 IGRT for prostate cancerimprudent to extrapolate to treatments using higher doses, treat-
ing larger target volumes or using more extreme forms of
hypofractionation where the clinical benefits of IGRT-R might be
more apparent. Previous non-randomised studies comparing
patient cohorts treated with IG-IMRT and 3D-CFRT [28,29] have
suggested improvements in grade 2 GU or GI side-effects using
IGRT but are compromised by differences in planning and delivery
techniques as well as differing dose constraints. Two randomised
trials have evaluated daily versus weekly image guided radiother-
apy. Tondel et al. reported no difference in acute patient reported
outcomes, despite dosimetric advantages seen with daily CBCT
and reduced margins, their late toxicity results are awaited [32].
A further study by de Crevoisier et al. showed no statistically sig-
nificant difference in recurrence free survival, with also no differ-
ence in acute toxicity [33]. A statistically significant difference in
late rectal toxicity and improvement in biochemical recurrence
was reported, albeit with a short median follow up of 4.1 years.
We found no evidence to suggest that IGRT was associated with
a reduction in disease control. IGRT may increase accuracy and
reduce the chance of underdosage in the target volume, alterna-
tively however it is possible that the reduced margins might lower
inadvertent dose outside the prostate which has been suggested as
a cause of treatment failure [34].
The IGRT experience gained within this study has facilitated
development of a new national trial PIVOTALboost (CRUK/16/018)
in which all patients receive IG-IMRT and are randomised to
receive pelvic lymph node IMRT or MR-directed dominant lesion
boosts using hypofractionated schedules as in the CHHiP study.
We have shown it is feasible to introduce prostate IGRT in a
national randomised trial and that reduced margins translate into
dosimetric benefits. Overall side effect profiles were low with and
without IGRT in the CHHiP trial and this substudy.Funding
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